Phase 2 N=87 AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
Non Small Cell Lung Cancer
Primary: Overall Survival — 29; 27; 13; 13 Participants — p=0.2069
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=19 The Effectiveness of Transcranial Direct Current Stimulation (tDCS) in Decreasing Food Cravings
Craving
Primary: Food Cravings — -26.81; -7.8 percentage of change in cravings
N/A N=73 Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
Chronic Migraine
Primary: Safety - Number of Participants With Adverse Events — 6; 5 Participants
N/A N=68 Reducing Risk in Cardiac Rehabilitation: Partners Together in Health (PaTH) Intervention Study
Coronary Heart Disease · Cardiac Rehabilitation
Primary: Healthy Lifestyle Behavior Was Physical Activity/Exercise in Patients — 25.8; 21.8 minutes per day — p=>.05
Phase 3 N=440 An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Acute Phase — 186; 186 Participants
N/A N=419 Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Percentage of Patients With Adverse Drug Reactions (ADRs) — 20.53 Percentage of participants
Phase 4 N=58 ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir
Influenza
Primary: Mean Symptom Severity Score During the 2015-2016 Influenza Season for Symptom Domains as Assessed Using the Influenza-Patient Reported Outcome (FLU-PRO™) Questionnaire…
Phase 3 N=320 A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Chronic Renal Failure · Chronic Kidney Disease
Primary: Mean Weekly Hemoglobin Level From Week 30 to Week 34: Maintenance Period — 10.17; 10.11 g/dL
Phase 4 N=103 Reducing Suicidal Ideation Through Insomnia Treatment
Insomnia · Depression · Suicidal Ideation
Primary: Scale for Suicide Ideation Index (SSI) — 4.66; 5.25 units on a scale
N/A N=40 Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Acromegaly
Primary: Change in Liver Fat — 0.03 Lipid/water ratio
Phase 2 N=125 A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival (OS) — 8.02; 9.82; 10.45 months
Phase 3 N=247 RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)
Meningitis, Meningococcal · Rotavirus Infections
Primary: Percentage of Participants Achieving Seroresponse for Meningiococcal Group C Serotype — 100; 100 Percentage of participants
Phase 4 N=50 Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
Asthma
Primary: Asthma Control — 1.857; 1.592; 1.792; 1.578 units on a scale — p=0.046
Phase 3 N=58 Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
Overactive Bladder · Urinary Incontinence
Primary: Improved Overactive Bladder Symptoms as a Measure of Efficacy of Mirabegron — 13; 14; 25; 6 Participants
Phase 1 N=324 Pharmacokinetics and Safety in Healthy Volunteers
Healthy
Primary: Area Under the Concentration Time Curve (AUC) From Time Zero to Infinity (AUC 0-∞) of BI 695501, US-licensed Humira® or EU-approved Humira® — 2630; 2470; 2650 microgram…